CD8A and neoplasm: In vivo, IAHA‐LaP/siPTPN6 NMs elevated the percentage of mature DCs in tumor‐draining lymph nodes, facilitated CD8+ T cell infiltration into tumors, and significantly inhibited primary tumor growth.[347] This NM design provides a novel strategy for enhancing STING pathway activation.